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Prioritizing GWAS Results: A Review of Statistical
Methods and Recommendations for Their Application
Rita M. Cantor,1,* Kenneth Lange,1,2 and Janet S. Sinsheimer1,2Genome-wide association studies (GWAS) have rapidly become
a standard method for disease gene discovery. A substantial
number of recent GWAS indicate that for most disorders, only
a few common variants are implicated and the associated SNPs
explain only a small fraction of the genetic risk. This review is
written from the viewpoint that ﬁndings from the GWAS provide
preliminary genetic information that is available for additional
analysis by statistical procedures that accumulate evidence, and
that these secondary analyses are very likely to provide valuable
information that will help prioritize the strongest constellations
of results. We review and discuss three analytic methods to
combine preliminary GWAS statistics to identify genes, alleles,
and pathways for deeper investigations. Meta-analysis seeks to
pool information from multiple GWAS to increase the chances
of ﬁnding true positives among the false positives and provides a
way to combine associations across GWAS, even when the original
data are unavailable. Testing for epistasis within a single GWAS
study can identify the stronger results that are revealed when
genes interact. Pathway analysis of GWAS results is used to prior-
itize genes and pathways within a biological context. Following a
GWAS, association results can be assigned to pathways and tested
in aggregate with computational tools and pathway databases.
Reviews of published methods with recommendations for their
application are provided within the framework for each approach.
Introduction
Genome-wide association studies (GWAS) have rapidly
become a standard method for disease gene discovery.
When they were ﬁrst conceived, it was thought that
GWAS would provide an effective and unbiased approach
to revealing the risk alleles for genetically complex non-
Mendelian disorders. The premise of the GWAS design is
that extensive common variation in the human genome,
as exhibited by SNPs with frequencies greater than 1%, is
responsible for the risk of most genetically complex disor-
ders. A controversy ensued as to whether much of this risk
could be explained by the older and more common gene
variants that GWAS were designed to detect or whether
much of the risk was likely to be caused by multiple rare
variants with frequencies less than 1%. That is, because
success in GWAS is contingent upon being able to statisti-
cally detect the association of an SNP that is in linkage
disequilibrium with a predisposing gene variant, that
variant would have to be at a sufﬁcient frequency in order
to detect it. It was expected that testing the genome with
dense SNPs that capture the linkage disequilibrium in
case and control samples would produce results that1Department of Human Genetics, 2Department of Biomathematics, David Ge
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disease, common gene’’ hypothesis were the rule. Thus, in
addition to their focus on revealing the biological contri-
butions to complex traits and disorders, the results of
GWAS also provide substantive information regarding
the extent of the contributions made by common variants
to complex traits and disorders.
GWAS require three essential elements: (1) sufﬁciently
large study samples from populations that effectively
provide genetic information regarding the research ques-
tion, (2) polymorphic alleles that can be inexpensively
and efﬁciently genotyped and cover the whole genome
adequately, and (3) analytic methods that are statistically
powerful and can be employed to identify the genetic asso-
ciations in an unbiased fashion. Each of these three
elements was developed for GWAS in just a few years,
and we brieﬂy summarize some of the speciﬁc accomplish-
ments. Regarding the ﬁrst element, a substantial number
of large study samples were formed through productive
collaborations. In many cases, the resulting sample sizes
provide sufﬁcient statistical power to identify relatively
small associations of common variants. The GWAS show
that for discrete phenotypes, most of the detectable odds
ratios are between 1.1 and 1.3.1 Thus, most of the signiﬁ-
cantly associated SNPs are in linkage disequilibrium with
predisposing variants that increase the carriers’ disease
risks by between 10% and 30% over the risk in noncarriers.
It is likely that there are many more common variants that
have not been detected by GWAS because they raise the
risk by smaller values, perhaps as low as 1%. However,
these undetected associations might be important, because
they may be effective in elucidating the biologic basis of
the disorders and suggesting treatments. Regarding the
second element, substantial numbers of SNPs throughout
the genome were identiﬁed by the HapMap Project and
placed in easily accessible databases. Product development
by technology companies used these SNPs and produced
accessible tools for high-throughput genotyping. These
tools have evolved to provide more dense coverage of the
genome at increasingly affordable costs. Third, and
perhaps most important in the context of this review,
a substantial number of analytic challenges have been
successfully addressed. Themost critical may be the thorny
problem of coordination of SNP genotypes among study
samples. This problem occurred with the recognitionffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
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that large samples were needed and that the individual
study samples that contributed to them were genotyped
on different and rapidly evolving microarray platforms.
Although this was problematic, investigators also viewed
it as a potential strength, because it provided the opportu-
nity to increase the number of SNPs tested for association
through imputation. Imputation is the use of additional
information to predict missing values in a sample. The
problem sparked intensive research efforts and the crea-
tion of appropriate software that exploited linkage dis-
equilibrium among SNPs and accurately imputed large
numbers of ‘‘missing’’ genotypes.2–4
Initially, it was anticipated that GWAS would reveal
a substantial number of statistically signiﬁcant associa-
tions for each disorder, requiring their prioritization for
follow-up studies. Saccone and colleagues provide an
extensive list of criteria to consider5 and amethod to apply
them. A genomic information network generates a score
representing the accumulation of evidence supporting
the biological relevance of each associated SNP. The inverse
of the overall score is used to weight the SNPs’ overall asso-
ciation p value. The score includes factors such as (1) occur-
ring in a gene that is part of an implicated pathway, (2)
playing a known functional role, (3) support from compar-
ative genomics, and (4) linkage information. Feasibility is
shown by applying the approach to identify genes for
nicotine dependence.
The substantial number of recent published GWAS indi-
cate that for most disorders, only a few common variants
are implicated and the associated SNPs explain only a small
fraction of the genetic risk,1 even if they are considered in
aggregate. The small estimated effect sizes have been disap-
pointing to some, and many current investigations are
now focused on pursuing sequencing studies to identify
the contributions of rare variants to the same disorders.
Rare variants, those that appear in less than 1% of the pop-
ulation, may even be private mutations that only appear in
a few individuals or families. Mutations with these low
frequencies have been seen in many Mendelian disorders.
For example, cystic ﬁbrosis (CF [MIM 219700]), which
occurs with an incidence of 1/3000 in individuals of Euro-
pean descent, has had at least 1500 variants, most of which
are autosomal recessive and fully penetrant.
Large-scale sequencing, which was once prohibitively
expensive, is more ﬁnancially feasible today and is likely
to become a common option in the future. It will provide
additional information regarding the genetic etiology of
complex disorders and will perhaps blur the boundary
between investigations of common and rare variants. The
rare variants, which will only be seen in a small fraction
of those who are affected, are expected to raise the risk in
carriers at a substantially higher rate than common vari-
ants, although this expectation remains to be investigated.
Sequencing studies in complex disorders will also be con-
ducted with the caveat that rare causal variants may be
even more difﬁcult to identify and interpret. If such vari-
ants are not found in coding regions with the possibilityTheof disrupting protein production, they may remain unse-
quenced, or their importance may go overlooked. As
with common variants in GWAS, rare-variant analyses
will present a large number of statistical challenges that
are likely to lead to the development of interesting and
useful methods that reveal important results.
Recently, one review and three commentaries describing
and evaluating the success of GWAS were published in
a single issue of the New England Journal of Medicine.1,6–8
Although focused primarily on whether GWAS met their
expectations, these salient publications each provide
some support for the position that GWAS are only the ﬁrst
step in the gene identiﬁcation process. More speciﬁcally,
the informative review by Hardy and Singleton deﬁnes
and explains many of the important GWAS concepts.8 It
also concludes that if the genetics of complex diseases is
comparable to a jigsaw puzzle, we have put the edges
and corners in place and now have a framework to pur-
sue the genetic etiology of complex disorders. Kraft
and Hunter6 advocate meta-analysis, the ﬁrst approach
reviewed herein, to provide more stable risk estimates
that can be translated into clinical information. In his
commentary, David Goldstein1 explains his signiﬁcant
concerns about the lack of detection of variants with sufﬁ-
cient effect sizes to explain the estimated heritabilities and
relative risks of complex disorders. Although he advocates
the detection and analysis of rare variants, he also indicates
that these differences may be explained by large interac-
tion effects, thus providing support for applying the
secondmethod we review. In his commentary, Joel Hirsch-
horn7 responds to the small effect sizes of many of the
nearly 250 associated variants that have been detected by
pointing out that we are making progress in detecting
the true targets of these analyses, the biologic pathways,
thus advocating the third approach that we review.
One can view the ﬁndings from GWAS as providing
preliminary genetic information available for additional
analysis by statistical procedures that accumulate evi-
dence. These secondary analyses are very likely to provide
valuable information that will help us prioritize the stron-
gest constellations of results. Here we review and discuss
some of the analytic methods that are currently being
applied to combine preliminary GWAS association statis-
tics to identify genes, alleles, and pathways for deeper
investigations. We anticipate that some of these methods
designed to aggregate GWAS results will also be adapted
to identify the contributions of rare variants to complex
disorders.
Thus, one can view single-SNP GWAS analyses as
a preliminary step in the gene identiﬁcation process, where
methods that help prioritize the more important results
should be applied, and this review is written with that
focus. Here we review and discuss three current methodol-
ogies that combine results to reveal larger effects in order to
prioritize them for future studies. The ﬁrst, meta-analysis,
seeks to pool information from multiple GWAS to increase
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positives. It provides a way to combine associations across
GWAS, even when the original data are unavailable. We
also discuss a related approach, Bayesian hierarchical
modeling, which allows the incorporation of other results
through a prior function.
The second approach searches for epistasis within a
single GWAS study in order to identify stronger results
that are revealed when genes interact. We discuss the
nature and parameterization of interaction models, and,
because it is impractical to consider all possible pairwise
interactions, we consider only those that include at least
one signiﬁcant result. Current approaches of model selec-
tion by lasso penalized ordinary linear regression and
logistic regression are explained in greater detail.
The third approach prioritizes alleles and genes by using
information from known pathways. Complex disorders
may result from the accumulation of the effects of genetic
variants within pathways. The pathway model is similar
to one that is polygenic; however, the genes and their
variants are drawn from only a few speciﬁc pathways.
Following a GWAS, association results can be assigned to
pathways with the appropriate computational tools and
pathway databases. Those who are developing statistical
methods to implicate pathways face many challenges,
because this is the least developed approach. For all three
methods, we enumerate guidelines that should be followed
when they are applied to GWAS data. Directions for future
research are also discussed.
Conducting Meta-Analyses to Prioritize Associations
Motivation
A frequent means of prioritizing GWAS results is to com-
bine studies via a meta-analysis. Meta-analysis is a well-
established and validated statistical approach for com-
bining evidence across any number of independent
studies, each of which is designed to examine the same
research hypothesis.9–12 Rather than use the original data
from these studies, which can be computationally cumber-
some and logistically difﬁcult, meta-analysis combines
their results. This approach has been advocated for genetic
analysis as a method of increasing power,13–16 and it has
been used extensively in reporting the ﬁndings of GWAS.11
In June 2009, a search of PubMed with the criteria ‘‘meta-
analysis AND genome-wide association study’’ revealed
113 articles. Meta-analyses have been used for many years
in statistics, and it is impossible to cover all of the concepts
in this review. Readers desiring more extensive coverage
are urged to consult two excellent and comprehensive
review articles addressing meta-analyses in GWAS.15,17
Factors to Consider
In the context of GWAS, meta-analyses combine compa-
rable test statistics across independent studies of the
same phenotype, weighting them by the conﬁdence in
the study-speciﬁc results. The deﬁnition of ‘‘comparable’’
is not straightforward and usually requires judgment and
a justiﬁcation by the investigators. Some criteria that8 The American Journal of Human Genetics 86, 6–22, January 8, 2010should be considered before studies are combined are the
ascertainment of the sample, the deﬁnition and measure-
ment of the trait or disorder under analysis, and the statis-
tics that summarize the association result. Ideally, the
GWAS used in the meta-analyses were all conducted with
the same ascertainment criteria on comparable popula-
tions and following the same study design, so that there
is exchangeability between the individuals used in the
studies.16 Of course, in practice, this degree of homoge-
neity is not always possible, but it can be approached by
using careful study design and cooperation between
groups at the early stages of the studies.18
Comparability may be difﬁcult to achieve when con-
ducting a cumulative meta-analysis that combines the
results of a new study with existing studies, because the
details of the prior studies may not be available. To test
for possible differences among the studies, researchers
check for evidence of heterogeneity.16,19 Two of the most
popular tests are I2 and Cochran’s Q.20 Ethnic stratiﬁcation
within and between studies is a source of heterogeneity
that can lead to falsely impressive p values. Genomic inﬂa-
tion factors can be used to correct the excess of false posi-
tives as well as to test for heterogeneity.15,18 There is a trade-
off, on one hand, between the power and knowledge to be
gained from the large sample size and, on the other hand,
the dilution of the effects and the difﬁculties in interpreta-
tion that arise when combining studies that actually
examine different research hypotheses. The research
hypothesis of a meta-analysis is in some sense an intersec-
tion of the research hypotheses of the individual studies.
When there is too much heterogeneity, the associations
can also be obscured. Heterogeneity tests can provide
some insight17; however, it is difﬁcult to know how strict
one should be in requiring homogeneity among the
studies. We recommend following the guidelines of Zintza-
ras and Lau,21 who advocate using cumulative and recur-
sive cumulative meta-analysis as well as careful examina-
tion of potential biases that could be the cause of the
heterogeneity.
Inclusion of a study based on a heterogeneity analysis is
not simply a statistical decision, because those SNPs that
show association may not provide the complete picture.
We consider three examples of meta-analyses requiring
decisions regarding the tradeoff between power and infor-
mation. The ﬁrst meta-analysis combines studies con-
ducted in two diverse populations. The SNPs that are asso-
ciated in both samples are prioritized over SNPs that are
associated in only one of the samples. Meta-analysis of
studies from the same population would lead to a larger
list of associations, although fewer of them will apply to
other populations. In a similar way, researchers have
combined studies of different but related diseases as
a way to increase power and ﬁnd common susceptibility
genes that provide insights to all of these disorders.22–25
Although this is a sensible approach, care must be taken
to avoid overinterpreting the results of such a heteroge-
neous analysis, particularly negative results. Effect sizes
for the SNP may differ and, in the extreme, may lead to
protection in one disease and susceptibility in another.
The second meta-analysis combines the results of an
analysis that includes covariates with the results of one
that does not include those covariates. The prioritized
SNPs would most likely be those SNPs whose associations
are largely independent of the covariates.Without recogni-
tion of this factor, information is incomplete, and valuable
associations may be lost. As a third example, consider
a meta-analysis combining studies that analyze a contin-
uous trait with studies that analyze the top quartile of
these trait values as cases and the bottom quartile as
controls. The prioritized SNPs will be those that show
a clear distinction between low and high trait values.
Thus, researchers need to consider the differences in ascer-
tainment or other aspects of the study designs that neces-
sitated treating the phenotype differently in the two
studies when interpreting their results.
Applications
Although many GWAS have used meta-analysis primarily
as a means of increasing power26 to achieve signiﬁcance
that exceeds a study-wide threshold,17 the results can
also be used to prioritize SNPs or genes for subsequent
studies.27–32 In a cumulative meta-analysis, a new assess-
ment is made each time a study is conducted, which is
readily adapted to multiple GWAS of the same phenotype.
Cumulative meta-analysis is a form of Bayesian analysis
where early studies play the role of the prior probability
distribution12,33 and the new studies contribute to the
posterior probability. By combining the results of multiple
studies, power is increased and the number of false posi-
tives caused by statistical ﬂuctuation is reduced over those
for a single sample. The expectation is that the true posi-
tive associations will rise to the top of the list.
As discussed previously, to obtain accurate meta-analysis
results, the studiesmust ask the same research question and
use similarly ascertained participants. The most common
research question for GWAS is whether the alleles at a
particular marker are associated with the disease status or
trait variability. Asking the same research question in each
study might appear to restrict the meta-analysis to the
intersection of SNPs genotyped in all of the studies.
However, imputed SNP results can be used provided that
similar procedures are applied in the imputation, the refer-
ence populations remain the same, and the researchers
carefully check for the effects of imputation error.15 In addi-
tion, there are explicit approaches to incorporate the uncer-
tainty due to SNP imputation into the meta-analysis.15,29
The results used in meta-analyses can be test statistics or
effect sizes. If test statistics are used, a variety of ways to
combine the results have been proposed. Traditional
approaches include Fisher’s method of combining p
values,34 and some researchers have used this method or
a weighted version inGWAS.35,36 These p value approaches
have disadvantages, most notably in that they cannot
provide an overall estimate of the effect size.17 GWASTheresearchers have also converted the individual test statis-
tics into z scores31,32,36,37 and used odds ratios when the
phenotype is dichotomous38 and regression coefﬁcients
when the phenotype is continuous.31,32,39
Weighting can provide more power and reduce the
effects of heterogeneity.40 Meta-analyses apply the prin-
ciple that, all else being equal, studies with large sample
sizes inspire more conﬁdence than studies with smaller
sample sizes.41 This is often reﬂected by using functions
of the study sample sizes or the inverse of the variances
of the estimates as weights.15 Inverse variance weights
can be estimated under a ﬁxed-effects model or under
a random-effects model.10,12 In general, ﬁxed-effects
models assume that all genetic variation between studies
is due to random error, whereas random-effects models
also allow variation due to real population differences
such as ethnic ancestry, study design, or phenotypic differ-
ences.42 Random-effects models handle the possibility of
heterogeneity among studies better. The range of weights
tends to be less extreme than the range seen in ﬁxed-effects
models. In general, a random-effects approach results in
more accurate estimates that generalize beyond the meta-
analysis samples. However, the standard errors will be
larger, reﬂecting an increase in uncertainty and making
the procedure more conservative. Importantly, Ioannidis
et al.42 point out that ﬁxed-effects models lead to overcon-
ﬁdence in results when there is heterogeneity between the
GWAS. This overconﬁdence could lead to false positives.
The ﬁxed-effects approach has been used most often in
GWAS meta-analysis,29–31,38,39 possibly because (1) there
are readily available tests of heterogeneity to detect this
potential problem,20 (2) accurate population estimates are
not critical when the goal is to prioritize loci for follow-
up, and (3) software for running the ﬁxed-effects approach
forGWASmeta-analysis is readily available (see for example
METAL, ameta-analysis tool for GWAS). However, random-
effects approaches have also been used43 and should
increase in popularity asmoreGWASdata become available
across a wide spectrum of populations, phenotypes, and
studydesigns andheterogeneitybecomesmoreof a concern.
For amore thorough discussion ofweighting options aswell
as other nuances ofGWASmeta-analysis,we againdirect the
reader to the review by Zeggini and Ioannidis.17
SNP prioritization after a meta-analysis has taken several
forms. Some investigators base their decision regarding the
SNPs most worthy of further study solely on the meta-
analysis p values,31,44 whereas others use predetermined
decision rules to allow other prior evidence as well as the
meta-analysis results to contribute to decisions.36,37 One
interesting application of this approach is to use the asso-
ciation results from one disease to identify candidate loci
for a second disease that cosegregates with the ﬁrst. For
example, Fisher and colleagues45 use the GWAS results
for Crohn’s disease (IBD1 [MIM 266600]) to uncover candi-
date loci from ulcerative colitis (IBD [MIM 266600]), and
Smyth and colleagues46 use GWAS analysis of type 1 dia-
betes (IDDM [MIM 222100]) as candidate loci for celiacAmerican Journal of Human Genetics 86, 6–22, January 8, 2010 9
disease (CD [MIM 212730]) and vice versa. Although this
approach is attractive, particularly in limiting the number
of tests performed, it can be hard to know how to weight
the evidence supporting cosegregating disease partners.
Bayesian approaches provide an objective way to use this
extraneous information.
Bayesian Hierarchical Models
Although the majority of meta-analyses are frequentist in
their focus, Bayesian meta-analyses also have a well-estab-
lished history.41 Because Bayesian approaches hold much
promise for GWAS and because they are not as well known
as their frequentist analogs, we describe them here in more
detail. Whittaker and colleagues47,48 developed GWAS
meta-analysis approaches that use hierarchical Bayesian
models. Thesemodels are hierarchical because they assume
prior distributions on the parameters. These priors in turn
depend on hyperparameters drawn from some distribu-
tion. By incorporatingHapMap linkage disequilibriumdata
as prior information, Whittaker’s models allow for multi-
marker effects to be inferred even if these results were
not part of the available data from the individual studies.
Thus, they allow SNP prioritization by borrowing strength
across neighboring SNPs. Because this method selects the
most highly associated set of SNPs in a region, it is highly
computational and poorly adapted to genome scans.
Bayesian hierarchical models can be used to generalize
meta-analysis so that researchers can incorporate evidence
from a wide variety of sources to create informative priors
for the current study.49,50 This evidence can include prior
linkage or association results, SNP functionality, sequence
conservation in multiple species, biological plausibility, or
in fact anything upon which the user is willing to place
a prior distribution. Both Lewinger and colleagues49 and
Chen and Witte50 take a hierarchical approach and model
the data or summary statistics of the data with parameters
whose distributions are functions of additional hyperpara-
meters. These distributions of hyperparameters depend on
the locations and function of pertinent SNPs. The appeal
of this approach over more computationally simple
weighting schemes is that the relative importance of the
additional data is not ﬁxed a priori but is instead deter-
mined as part of the model.
The goal is to determine the posterior probability of asso-
ciation for each SNP and then use these posterior probabil-
ities to prioritize the SNPs for additional study. In a fully
Bayesian approach, this probability is calculated by inte-
grating the joint probability over all possible values of
the hyperparameters. In GWAS with so many hypotheses
to test, this approach is computationally prohibitive.
Therefore, both Chen and Witte50 and Lewinger and col-
leagues49 rely on empirical Bayes approaches, where the
most probable values of the hyperparameters are calcu-
lated from themarginal likelihood of GWAS data and cova-
riates. The probability of association is then calculated
conditional on these values for the hyperparameters as
well as the observed data.10 The American Journal of Human Genetics 86, 6–22, January 8, 201Although the hierarchical Bayesian approach is quite
appealing and Witte provides R code on his website, we
could not ﬁnd any published reports of GWAS using this
approach. This omission is possibly because of its compu-
tational complexity relative to meta-analysis or because it
is still difﬁcult to decide which auxiliary covariates to use
and what values to use for the priors. There is no consensus
about what information should be used to create the prior
support or what the appropriate forms for the prior distri-
butions are. Both Lewinger et al.49 and Chen and Witte50
use gene conservation across species as well as the SNP’s
function as priors, but they deﬁne the priors in different
ways. In addition, Lewinger et al.49 include expression
results but do not include prior linkage or association
results, whereas Chen and Witte50 use association and
linkage results but not expression results.
Modeling Epistasis to Prioritize Associations
Motivation
SNPs that combine tomake larger genetic effects can statis-
tically reﬂect an epistatic interaction, where the alleles of
one gene inﬂuence the effects of alleles of another on a trait
value or risk of disease. These interactions are by deﬁnition
nonlinear and thus can dramatically increase the trait or
risk. Epistatic interactions that have been identiﬁed in
humans include the interactions between the RET proto-
oncogene (RET [MIM 164761]) and endothelin receptor
type B (EDNRB [MIM 131244]) genes in Hirschsprung
disease51 (HSCR1 [MIM 142623]), the taste receptor genes
taste receptor type 2 member 16 (TAS2R16 [MIM 604867])
and taste receptor type 2 member 38 (TAS2R38 [MIM
60775]) in nicotine dependence52 (MIM 188890), the
interleukin 4 receptor (IL4 [MIM 147780]) variants and
interleukin 13 (IL13 [MIM 147683]) promoter variants
in asthma53 (MIM 600807), and the alpha- and beta-
adrenergic receptors (ADRA2A [MIM 104210] and ADRB2
[MIM 109690]) in congestive heart failure54 (MIM 212112).
Finding an interaction between SNPs increases their
priority for further study.
Despite an acceptance of the importance of epistatic
interactions, they have been difﬁcult to detect. Most
computers can easily handle the marginal analysis of
hundreds of thousands of SNP predictors, but the assess-
ment of all pairwise or higher-order interactions requires
much greater computational resources and novel statistical
approaches that are less computationally intensive. For
example, likelihood ratio tests for interactions require
repeated maximum likelihood estimation, whereas score
tests are much less computationally intensive. However,
score tests do not provide estimates of effect sizes. In the
context of GWAS studies, interaction effects without prior
hypotheses of the important alleles are far more difﬁcult to
detect than main effects. That is, if association studies are
underpowered relative to main effects, they have almost
no chance of picking up interaction effects when all possi-
bilities are explored. Even current studies with ten of
thousands of participants have trouble detecting and0
conﬁrming interactions when large numbers of SNPs are
typed. The combinatorial explosion of possible interac-
tions creates enormous difﬁculties in estimation, multiple
testing, and overﬁtting. In GWAS, even for main effects,
the number of predictors far exceeds the number of obser-
vations. Exhaustive examination of all pairwise interac-
tions is possible, but for multiway interactions the task is
totally impractical. We recommend making a compromise
by conducting less computationally intensive score tests
on all predictors and reserving more intensive likelihood
ratio testing and parameter estimation for those predictors
with the most signiﬁcant score statistics.
Before moving on to discuss speciﬁc methods to detect
epistasis, we consider how to prioritize the results of
a GWAS that includes testing for interactions. Although
it is not required that an SNP be involved in interactions
to make it worthy of continued study, evidence of one or
more interactions provides additional support. We advo-
cate prioritizing SNPs that are most associated with a trait
regardless of whether that association takes the form of
a main effect or an interaction.
Statistical Methods
Interaction modeling has a long history in statistics, and it
is impossible to do justice to the topic in this review.
Readers wanting more extensive coverage are urged to
consult two excellent comprehensive review articles.55,56
Here we stress some recent advances in data mining that
can be used to prioritize GWAS results. In dichotomous
traits, logistic regression has been used to conduct associa-
tion tests for GWAS; alternative tests of equality of propor-
tions or Fisher’s exact test lack the ﬂexibility to handle
multiple predictors. For continuous traits, linear regression
has been used for GWAS. A major strength of regression is
that it easily provides an opportunity to include interac-
tions. Among the other advantages of regression analyses
are (1) explicit parametric models; (2) stable algorithms
for parameter estimation; (3) availability of likelihood
ratio and F tests for both main effects and interaction
effects; (4) easy incorporation of covariates such as age,
sex, and ethnic origin; and (5) wide availability of reliable
and well-documented software. Most of the disadvantages
relate to the scale of current data sets and the excess of
predictors over observations. Among the disadvantages
are (1) failure of normality assumptions for quantitative
traits, (2) breakdown of large sample approximations
behind p values, (3) failure of search algorithms in under-
determined problems, (4) proneness to overﬁtting, (5)
failure to deliver spare solutions, and (6) the hierarchical
nature of the model selection requiring detection of
main effects before detecting interaction. Before explain-
ing how some of these defects can be addressed, it is useful
to brieﬂy summarize some of the alternative methods to
detect epistasis.
The burgeoning ﬁeld of data mining57 offers many
avenues to understanding interactions. Certainly, logistic
regression and discriminant analysis are closely allied. InTheprinciple, any method of discriminant analysis can serve
to separate cases from controls. Discriminant analysis
methods such as CART (classiﬁcation and regression trees)
and random forests are obviously relevant to interaction
modeling.58 Other, more tailored contenders include the
multifactor dimensionality reduction method,59–61 the
combinatorial partitioning method,62 and the restricted
partition method.63 Although these tools are helpful in
exploratory data analysis and excel in discriminating cases
from controls, they suffer from several limitations. For
example, purely combinatorial methods do not yield effect
sizes or p values and are incapable of handling covariates.
Depending on the algorithm employed, they can easily be
overwhelmed by large numbers of predictors and the
demands of cross-validation and permutation testing. In
response to these criticisms, some methods are being rede-
signed. For instance, Lou and colleagues52 have revised the
multifactor dimensionality reduction method64 to allow
for covariate adjustment, analysis of both continuous
and binary traits, and pedigree data. Their new formula-
tion owes an intellectual debt to the FBAT (family-based
association test) method.65,66 Other innovations include
introduction of entropy and conditional entropy mea-
sures of interaction67,68; exploitation of proximity mea-
sures between individuals69–71; and application of neural
networks,72 genetic programming,73 logic regression,74
pattern mining,64,75 and Bayesian partitioning76.
The need for objective evaluation of this bewildering
array of methods is obvious. Cordell55 stresses the impor-
tance of computational speed in handling massive SNP
data sets. As a practical matter, statistical methods and
software are inextricably intertwined. On the basis of
computational speed, and presumably of ease of use,
Cordell prefers the programs PLINK,77 Random Jungle,78
and BEAM,76 implementing standard regression, random
forests, and Bayesian partitioning, respectively. Musani
and colleagues56 are less speciﬁc in their recommendations
and suggest that a combination of methods may serve
consumers best. In our own research, we primarily use
PLINK77 for classical regression and Mendel79 for lasso
penalized regression.80–82 PLINK is user friendly, with
built-in data management and quality-control routines.
Mendel has fewer diagnostics but excels in model selection
when the number of SNPs far exceeds the number of indi-
viduals.
Before describing improvements to traditional para-
metric models, let us brieﬂy mention some study design
issues. In case-only designs, one looks for nonindepen-
dence of marker genotypes. Among the possible tests for
departures from independence, it is worth singling out
chi-square tests, entropy, and max Z scores. These tests
have considerable power, but one should keep in mind
their limitations. Because they do not permit covariates,
they are susceptible to population stratiﬁcation and
linkage disequilibrium. The underlying contingency tables
may be sparse, so permutation evaluation of p values is
a good idea. Unfortunately, permutation testing comes atAmerican Journal of Human Genetics 86, 6–22, January 8, 2010 11
a price of much heavier computation. At the other
extreme, pedigree data also entail real challenges. Unless
driven entirely by linkage disequilibrium, linkage analysis
requires pedigrees.
Ascertainment may be a problem, appropriate test statis-
tics are not always obvious, and combinatorial or linear
algebra barriers rapidly mount. For these and other
reasons, most geneticists are reluctant to abandon random
sample or case-control study designs.
Nature and Parameterization of Epistatic Models
For the sake of this discussion, we deﬁne epistasis explicitly
as deviation from linearity under a general linear model,
that is mi¼ dþ b1xiþ b2yi versus mi¼ dþ b1xiþ b2yiþ gxiyi,
where i denotes individual, xi and yi are two predictors, b1
and b2 are their main effect sizes, d is the intercept, and g is
the effect size for the interaction. In ordinary linear regres-
sion, trait variation is fully speciﬁed by a common variance
s2 and a mean mi speciﬁc to each person i. The residuals,
the deviations from the expected trait values, are assumed
to be normally distributed. In logistic regression, the vari-
ance parameter s2 disappears, and the quantity mi is used
to estimate the odds
Pðzi ¼ 1 j giÞ
Pðzi ¼ 0 j giÞ ¼ e
mi :
Suppose individual i has genotype gi and trait value zi. In
the absence of nongenetic predictors, the most general
model for a single SNP involves setting
mi ¼ 1fgi¼1=1ga1 þ 1fgi¼1=2ga2 þ 1fgi¼2=2ga3:
Here, 1C equals 1 when the condition C is true and
0 otherwise. The three parameters a1, a2, and a3 are
reduced to two in the additive model as a result of the
constraint a2 ¼ 12ða1 þ a3Þ. For initial screening, the addi-
tive model is adequate for two reasons. First, nature does
act linearly in many cases. Second, if the minor allele fre-
quency is low, then there will be little data to estimate
the effect of the rare homozygote. Another reason for
preferring the additive model is that the resulting test
requires only one degree of freedom, rather than the two
degrees of freedom required for the test under the general
model. Thus, we recommend using the additive model
for initial GWAS screening.
Epistatic modeling brings in a second SNP and more
parameters. Suppose person i has genotype gi at the ﬁrst
SNP and hi at the second SNP. In the full epistatic model
given by Cordell,55
mi ¼ 1fgi¼1=1,hi¼1=1gg1 þ 1fgi¼1=1,hi¼1=2gg2 þ 1fgi¼1=1,hi¼2=2gg3
þ1fgi¼1=2,hi¼1=1gg4 þ 1fgi¼1=2,hi¼1=2gg5 þ 1fgi¼1=2,hi¼2=2gg6
þ1fgi¼2=2,hi¼1=1gg7 þ 1fgi¼2=2,hi¼1=2gg8 þ 1fgi¼2=2,hi¼2=2gg9:
This should be contrasted to the additive model, where
the effects of the two loci are independent of one another:
mi ¼ 1fgi¼1=1ga1 þ 1fgi¼1=2ga2 þ 1fgi¼2=2ga3
þ1fhi¼1=1gb1 þ 1fhi¼1=2gb2:12 The American Journal of Human Genetics 86, 6–22, January 8, 201Interaction can be tested by an F test or a likelihood ratio
test. In the additive model, the term 1fhi¼2=2gb3 is not
omitted by accident. It is redundant because in its pres-
ence, mi is invariant under the substitution of aj þ c for aj
and of bk  c for bk for any constant c.
With this degree of generality, testing for interactions
results in a four-degrees-of-freedom test. To increase power,
it is desirable to avoid the complexity of the full model.55 If
there is evidence for dominant or recessive effects, restric-
tions can be placed on the parameters that will reduce the
degrees of freedom. In the absence of this information,
assuming that the allelic effects are additive provides
a reasonable compromise between genetic truth and parsi-
mony. In that case, the interaction model with has ﬁve
parameters and the additive model has four, for a single-
degree-of-freedom test. Let xi equal 1, 0, or 1 according
as gi equals 1/1, 1/2, or 2/2. Similarly, let yi equal 1, 0,
or 1 according as hi equals 1/1, 1/2, or 2/2. In the simpliﬁed
interaction model, mi ¼ g1 þ xig2 þ yig3 þ xiyig4. Here,
interaction is tested by deciding whether g4 ¼ 0. In prac-
tice, one should standardize the predictor values yi to
have mean 0 and variance 1.
In her recent review, Cordell55 discusses tests of associa-
tion allowing for interactions. In the context of the gener-
alized linear model, assuming the allelic effects are addi-
tive, association of ﬁrst SNP allowing for interaction with
second SNP is tested by deciding whether g3 ¼ g4 ¼ 0.
These tests will be less powerful than a single-locus test
of association when there are no interactions, but they
can be more powerful when there are interactions.3
Inprinciple, there is nothing toprevent thesemodels from
being implementedonpedigreedataasmeaneffects inavari-
ance component model. In variance component models,
computation time scales as the cube of the number of people
within a pedigree, so screening vast number of interactions
with large pedigreeswould be unrealistic. Instead,we recom-
mend testing for interactions with pedigree data in an
attempt to replicate interactions detected as part of
a GWAS. A beneﬁcial side effect would be simultaneous
adjustment forthepolygenicbackground.Whenusingavari-
ance component model, a binary trait, such as disease affec-
tion status, can be treated as a quantitative trait that takes on
only two values, zero andone. To our knowledge, no onehas
programmed this measured genotype model82 with interac-
tions, but it is clearly feasible in existing software.79,83
Prioritizing SNPs for Interaction Testing
The sheer number of interaction models is one of the






znk=k! k-way interactions. For n¼ 106 SNPs,
this translates into nearly 5 3 1011 possible pairwise inter-
actions. Whether testing this many potential interactions
is feasible depends on computing resources. Ma and
colleagues84 calculate that it would take 5 years to conduct
this many t tests where they use linear regression to esti-
mate the parameter values and their standard errors on0
their single-processor machine with 2000 individuals.
Parallel computing reduces this time considerably,3,84 but
analyzing 5 3 1011 interactions with data from thousands
of individuals takes weeks or months to complete.55 As
a separate issue, the problem of false positives versus power
due to multiple testing is even more of a concern than it is
for testing GWAS main effects.
Three strategies have been suggested to reduce the
number of pairwise interactions considered. First, one
can identify the top m marginal predictors and look at






¼ 4950 models. The second strategy
is to consider all predictors paired with the top m predic-






For our example, nm ¼ 108, which is a considerable
increase over the number with the ﬁrst strategy. The third
strategy targets speciﬁc SNP pairs. These may be identiﬁed
through protein-protein interactions, regulation by a com-
mon transcription factor, or participation in a common
biochemical pathway.85–87 The net cast can be wide or
narrow. This approach overlaps with the approach of using
molecular pathways to prioritize GWAS results that is
discussed in the next section.
All three strategies involve a tradeoff between mini-
mizing computation and multiple comparisons and maxi-
mizing power. Researchers can try all three strategies, but
they should be honest about how ﬁnely they sift the data
and adjust their criteria for choosing SNPs for follow-up.
Strategy three may ultimately be the one of choice, but
as discussed in the next section, currently it runs the risk
of missing many important connections. The knowledge
of networks stored in current databases is not up to the
task. The more agnostic strategies one and two are perhaps
safer if one is willing to pay the price of more multiple
comparisons. In our own program Mendel,79,80 the user
can specify any of the three strategies.
Detecting Epistasis with Penalized Regression
A variety of alternative methods to classic regression have
been proposed for detecting interactions. Cordell55
provides a comprehensive review of Bayesian model selec-
tion approaches, penalized regression, and data-mining
methods, including tree classiﬁcation. Rather than repeat
her comments, we focus speciﬁcally on one approach,
lasso penalized regression,80,81,88,89 that is particularly well
suited to GWAS interaction detection when the number of
SNPs vastly exceeds the number of subjects.
We begin by pointing out the difference between select-
ing interactions and formal testing of interactions. As
a matter of principle, geneticists do not accept a single
study as deﬁnitive, and all important ﬁndings are subject
to replication. This attitude, whether justiﬁed or not in
a preliminary study, places the emphasis on ﬁnding the
most important SNPs for further study rather than on
declaring their global signiﬁcance. So instead of settingThea signiﬁcance level and only following up on interactions
whose p values are smaller than that signiﬁcance level, it
is just as sensible to ﬁx some number m, identify the m
most signiﬁcant associations, and then target these for
follow-up with interaction studies. The value of m depends
on resources. Because predictors are often correlated, via
linkage disequilibrium, the m most signiﬁcant predictors
identiﬁed by simple linear regression may not constitute
an optimal set for follow-up.
Fortunately, penalized regression is an ideal vehicle for
ﬁnding a small subset of potent but weakly correlated
predictors. This computational advance performs con-
tinuous model selection while avoiding some of the
drawbacks of traditional forward and backward stepwise
regression. It is also exceptionally quick computation-
ally and adapts readily to allow screening of multiway
interactions.
During the last 20 years, statisticians began to consider
data sets where the number of predictors far exceeds the
number of observations, precisely the situation in GWAS.
Prior experience with shrinkage estimation suggested to
statisticians and other mathematical scientists88,90–93 that
adding penalty terms to the likelihood or other objective
function might stabilize parameter estimation. It soon
became apparent that the form of the penalty was crucial.
A ridge penalty, basically a sum of squares, was the most
obvious choice for a penalty. After considerable experi-
mentation and reﬂection, statisticians discovered that
a sum of absolute values is more effective. This lasso
penalty not only shrinks parameter estimates, it also zeros
out the majority of them, thus achieving model selection.
The strength of the penalty determines the number of
predictors that enter a model.
Several authors have explored lasso penalized ordinary
regression81,89,94–96 in both the l1 (least absolute deviation)
and l2 (least-squares) settings. Much of their work is largely
preserved in logistic regression.80 To move from ordinary
to logistic regression, one simply substitutes the negative
loglikelihood for the loss function. Logistic regression
takes two to three times longer than ordinary regression.
This approach to the identiﬁcation of epistatic interactions
is programmed and available in the Mendel software. The
British celiac GWAS data97 were analyzed for epistasis
with the lasso regression module.80 In an analysis of the
50 most signiﬁcant associations, epistatic interactions
between two human leukocyte antigen (HLA) SNPs and
three SNPs on chromosomes 2, 3, and 8 were observed.
It is particularly noteworthy that the univariate GWAS
p values for these three non-HLA SNPs, considered as
marginal effects, are far less impressive than their univar-
iate p values as epistatic effects. Strong epistatic effects
involving major histocompatibility complex (MHC) loci
are not limited to celiac disease and may be a hallmark of
diseases such as type 1 diabetes that have a strong associa-
tion with MHC loci. For example, Barrett and colleagues27
found a strong interaction between MHC loci and four
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attenuated when an MHC risk allele is present. These anal-
yses suggest that strong epistatic effects can be helpful in
prioritizing SNPs for further study.
GWAS Pathway Analysis
GWAS pathway analysis (GWASPA) provides a means of
integrating the results of a GWAS and the genes in a known
molecular pathway to test whether the pathway is associ-
ated with the disorder. This approach is compelling, in
that it addresses two important elements of post-GWAS
prioritization: the selected pathway provides a biological
vehicle for statistically combining GWAS association
results, and an implicated pathway provides a biological
interpretation. However, although GWASPA is appealing,
the analytic methods are at an early stage of development,
and additional factors regarding study design and statis-
tical analysis need to be addressed. Here we (1) provide
a conceptual framework and motivation for GWASPA, (2)
highlight the factors to include, (3) present some online
pathway resources, and (4) discuss design and statistical
issues for successful GWASPA. Throughout this section,
publications that identify and address analytic issues in
GWASPA are reviewed, and guidelines for conducting
GWASPA with the currently available tools are suggested.
We do not discuss the methods that are being used to
develop and establish pathways in this review, although
GWAS results could also be used to support that process.
Defining Pathways and GWASPA Motivation
Although the term ‘‘pathway’’ is often used to describe
molecular processes, its deﬁnition and application are
context dependent. Pathways have been used to represent
a wide range of biological processes that include cell func-
tions,metabolicprocesses, biosynthesis, genetic information
processing such as DNA repair, cell signaling, immune
responses, features of embryo development, and factors
leading to human diseases. In the context of the cell,
a pathway represents a series of actions among molecules
that lead to a particular endpoint or cell function. The genes
that coordinate toachievea speciﬁc taskaregrouped together
in the same pathway to reﬂect that process. Those genes are
sometimes referred to as gene sets and are often put on
a pathway diagram that indicates the order in which the
genes act and interact within the pathway. Alternative paths
involving the same or different genes that lead to the same
end result are also part of the pathway. There is a growing
list of pathways that are at varying stages of completion,
and the same genes appear in many of them. In addition,
there may be ambiguity about the structure of a pathway,
makingpathwaydevelopmentanactive areaof investigation
and the application of pathwaymethods difﬁcult to conduct
with certainty. Given these constraints, GWASPA, although
compelling on a theoretical level, have been challenging to
apply and interpret. The application of pathways is likely to
identify larger genetic effects than those seen with GWAS,
and a recent commentary on GWAS7 advocates GWASPA as
the next step in the process of GWAS data mining.14 The American Journal of Human Genetics 86, 6–22, January 8, 201A plausible model that motivates the application of
GWASPA derives from the recognition that biological
processes result from reaching successful endpoints in
multiple molecular pathways and that a sufﬁcient number
of small disruptions in a sufﬁcient fraction of those path-
ways may lead to a disorder. This molecular genetic model
is similar to the older statistical multifactorial/threshold
model (MTM), which postulates that small equal and addi-
tive variants in the genes that contribute to a biological
process accumulate until a risk threshold is crossed, result-
ing in a disorder. The classic disorder that illustrates the
MTM is the birth defect of cleft palate98 (CL/P [MIM
119530]), where the closing of the structure that becomes
the palate is contingent on a number of successfully timed
molecular processes. If we postulate that the variants that
accumulate are in genes contained within pathways that
control palate closure, a GWASPA can be viewed as
a natural extension of the MTM when SNP association
data are available. A GWASPA of cleft palate would be
accomplished by identifying the associated GWAS SNPs,
postulating the likely pathways involved during fetal
development, and connecting them analytically.
Pathway heterogeneity is an important factor, because
disruptions in different pathways are likely to lead to the
same disorder. Although affected individuals may share
the same disrupted pathways, the mutated genes or vari-
ants within those pathways are likely to differ. GWASPA
accommodate and capitalize upon this substantial degree
of genetic heterogeneity. In addition, multiple GWAS are
easily combined in a way that is potentially more powerful
than the combinations of individual genes by meta-anal-
yses. Genetic heterogeneity among ethnic groups, which
has been a source of concern in GWAS, will not affect
GWASPA if ethnic groups each contribute associations
with different genes and alleles in the same pathways.
This strength of GWASPA is illustrated by the analysis of
the IL12/IL23 pathway in multiple ethnic groups having
Crohn’s disease99 (IBD1 [MIM 266600]).
Critical Factors for a GWASPA
A successful GWASPA involves ﬁve steps that are enumer-
ated here and discussed in greater detail subsequently.
The ﬁrst step is to select one or more pathways for the
GWASPA. Biological insight and perhaps postanalysis
examination of GWAS results drive this. The second is to
select the most appropriate database (or databases) to
delineate the genes in the pathway (or pathways). There
is substantial variation regarding the genes in pathways
named to represent the same process, and the speciﬁc
genes that comprise them may be contingent upon the
database used. The third is to assign the GWAS SNPs to
known genes within the selected pathway, as given in
the selected database. Rules for gene assignment or
SNP exclusion are required because, given our current
knowledge of the genome, a substantial number of the
SNPs on GWAS platforms do not explicitly tag particular
genes. The fourth requires a pathway scoring system that0
addresses the biases inherent in the unequal distribution of
SNPs among pathways resulting from differences in
pathway and gene size and SNP density. The ﬁfth is to
identify a statistical approach for aggregating the GWAS
results that allows one to formally test the selected
pathway for association with the disorder under analysis.
Choicesmade for these ﬁve factors will have a substantial
impact on the GWASPA outcome, and our recommenda-
tion is that each of the factors be addressed and justiﬁed
for each study. Although ﬁxed guidelines would simplify
GWASPA substantially by providing analytic tools that
streamline the process, they would also remove much of
the creativity from the studies in this nascent stage of devel-
opment, making their development and application
premature. Therefore, we suggest and anticipate that
GWASPA for a given trait will be tailored based on the inves-
tigators’ backgrounds, biological insights making it doubt-
ful that ﬁxed guidelines about the choice of database, algo-
rithm to tag genes with SNPs, or statistical test will be
constructive. However, GWASPAmanuscripts should be ex-
pected to justify the choices, and their results should be in-
terpreted in a context-speciﬁc manner. The next subsec-
tions are written to help elucidate those choices.
Identifying Pathways for GWASPA
There are two general approaches to identify pathways for
GWASPA. The ﬁrst and most straightforward is to formu-
late a prior hypothesis regarding the pathways that are
likely to be involved in the disorder. This approach is
similar to the one used in candidate gene studies. Testing
candidates has become obsolete given the unbiased nature
of GWAS, but as yet, no approach to an unbiased evalua-
tion of pathways has been proposed, and selecting ‘‘candi-
date pathways’’ remains the method of choice for prior
selection. As an example, the pathways containing genes
associated with inﬂammation are good candidates for
GWASPA of autoimmune diseases. Multiple inﬂammation
pathways can be tested for a single autoimmune disorder,
or GWAS of multiple autoimmune disorders can be com-
bined in the same GWASPA. The differences in genotyping
platforms and sample sizes will have to be considered, just
as they are when conducting a meta-analysis.
The second approach uses the results of the GWAS to
guide the choice of candidate pathways. Tests that use this
information are biased by the observed results, and
although the methods of analysis are the same as those in
the ﬁrst option, the results will have to be interpreted
within this context. That is, the GWASPA merely assess
whether the accumulated data are consistent with a role
for the pathway. We recommend that replication in an
independent study sample be performed to implicate the
pathway formally. If replication samples are available, this
approach provides an appealing GWASPA study design.
Choosing Pathway Databases for GWASPA
Information regarding the structures of speciﬁc pathways
is stored within web-based databases. A comprehensiveThelisting of these pathway resources is in the Pathguide,
which currently provides information for about 300 data-
bases that are evolving rapidly in both size and number.
Among those described, the Kyoto Encyclopedia of Genes
and Genomes (KEGG) is easy to access and commonly
used. It is being developed at Kyoto University and
provides gene lists, diagrams, and pathway classiﬁcation
tools for many aspects of biology. Alternatively, the Gene
Ontology (GO) project seeks to provide a set of structured
vocabularies for speciﬁc biological domains that can be
used to describe gene products in any organism. It was
initiated by scientists associated with model organism
databases, and each of these model organism information
systems is annotating genes and gene products with GO
vocabulary terms. Tools enabling curators and researchers
to query and manipulate the vocabularies are provided.
Analogous information is provided in the Database for
Annotation, Visualization and Integrated Discovery
(DAVID) and Protein ANalysis THrough Evolutionary Rela-
tionships (PANTHER). These databases were built sepa-
rately, address different audiences with different research
questions, and are evolving as our knowledge of pathways
continues to develop. Thus, GWASPA results will be con-
tingent upon the pathway resource used, which is clearly
illustrated in a recently published study by Elbers and
colleagues.100 The authors use several currently available
databases to conduct GWASPA of the sameWellcome Trust
Case Control Consortium (WTCCC) data, a publicly avail-
able resource. They conclude that although the analyses
can highlight the relevant gene associations, the results
are likely to be biased by which database is used. The
authors ﬁnd that the differences in study outcome reﬂect
the differences in the pathway information included in
the resource and the way in which the information is orga-
nized. Thus, for GWASPA, we recommend using several
databases for a single pathway and incorporating an algo-
rithm for deciding whether the pathway is associated
when the results are inconsistent across the databases.
Assigning SNPs to Genes in Pathways
Once the pathway and database (or databases) are selected,
SNPs in the GWAS panel should be assigned to speciﬁc
genes in the pathway. Current genotyping platforms select
SNPs based on linkage disequilibrium patterns that sup-
port coverage of the base-pair positions across the chromo-
somes rather than coverage of genes in particular path-
ways, making assignment of some SNPs difﬁcult. This
problem has already been observed in GWAS, where strong
associations have sometimes been difﬁcult to interpret
because of the location of the SNP in relation to the ﬂank-
ing genes. For SNPs in the coding and known regulatory
regions, assignment is straightforward. For the other
SNPs, rules for assignment should be made, although
they are likely to be considered arbitrary. As an example,
Torkamani and colleagues,101 who are interested in illus-
trating the polygenic and multiple-pathway nature of
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mapping to multiple genes. They set a speciﬁc hierarchy
for gene elements to help with their assignment, where
their scheme is coding > intronic > 50UTR > 30UTR > 50
upstream > 30 upstream. It is difﬁcult to assign SNPs that
are 500 or more kb from a known gene, and these may
have to be excluded from the analysis. We recommend
constructing a formal rule for assigning SNPs to genes
based on themost current research regarding this problem.
Scoring Pathways in an Unbiased Fashion
Several sources of bias that derive from the differences in
pathway and gene size and SNP density must be addressed.
Well-developed pathways are more likely to be included in
the publicly available databases and are therefore more
likely to be identiﬁed by GWASPA. Larger pathways con-
taining greater numbers of genes, and thus larger numbers
of genotyped SNPs, are expected to show more associated
SNPs by chance alone. These introduce bias into GWASPA.
SNP density is not consistent among genes and contributes
a similar source of bias. Unless corrections are made, there
is bias toward implicating the pathways that are large and
well known with large genes that are more densely covered
by the SNPs in the GWAS panels. This problem has been
recognized by some investigators applying GWASPA.
Currently, the most frequent approach is to select a single
SNP with the strongest association signal from each gene.
This is not optimal, because it does not remove all of the
bias, and the signiﬁcance of pathways that contain a few
genes with multiple independent association signals may
be lost. In a recent analysis, Holmans and colleagues102
correct for linkage disequilibrium among SNPs and gene
size by only counting each gene once in the analysis,
regardless of how many signiﬁcant associations were
observed. Yu and colleagues103 also treat genes as the units
of analysis, and for each gene they provide the most signi-
ﬁcant multiple testing-adjusted p value. Wang and col-
leagues104 also focus on the gene and use the SNP with
the most signiﬁcant permutation p value to represent it.
They recognize that although only one SNP is used per
gene, the size of the gene and pathway and the density
of SNPs are still factors that could contribute to the type
1 error. The authors use an enrichment score based on
a weighted Kolmogorov-Smirnov running sum statistic
calculated for the genes in the known pathway, and to
address bias, this enrichment score is normalized so that
different pathways are directly comparable.
Statistical Considerations in GWASPA
A formal GWASPA includes a test statistic that reﬂects the
aggregation of GWAS associations for the genes in the
tested pathway. The observed value of the statistic is
compared to its expected value under the null hypothesis
of no association with the pathway and compared to its
standard error. It is difﬁcult to formulate a null distribution
from which to derive these values. Permutation tests have
been conducted to assess signiﬁcance, and fortunately,
they can also be used to adjust for many sources of bias.16 The American Journal of Human Genetics 86, 6–22, January 8, 201A choice of what to permute is sometimes not straightfor-
ward; the investigators may have to use the original geno-
type data, and the computational burden can become
substantial. It is alsopossible to construct anull distribution
with scores from the pathways that are deemed unlikely to
be associated with the disorder, but each pathway has
a different conﬁguration, making the choices for this anal-
ysis arbitrary. Additional factors thatmust be considered are
the choice of a cutoff value for classifying a gene as having
apositive signal, themethods bywhich thepvalues are esti-
mated and aggregated, the approach used to correct for
multiple testing, and the level of signiﬁcance that is set to
implicate a pathway. We recommend justifying these
choices in reporting and interpreting GWASPA. Methods
presenting options for these choices are discussed below.
The scarcity of formal GWASPA methods has not been
a deterrent to their application. The manuscripts devel-
oping and using this approach are creative and provide
encouragement, although there are clear ambiguities in
their ﬁndings. Lesnick and colleagues105 demonstrate that
SNPs in the axon guidance pathway collectively predispose
to Parkinson’s disease (PD [MIM 168600]) even though no
individual SNP reaches genome-wide signiﬁcance level;
Dinu and colleagues106 show that multiple complement
factor pathway genes, in addition to complement factor
H, are associated with the risk for developing age-related
macular degeneration (ARMD1 [MIM 603075]); and Ask-
land and colleagues107 implicate genes mediating ion
channel activity and synaptic neurotransmission in bipo-
lar disorder (MAFD1 [MIM 125480]), illustrating the broad
application of GWASPA.
Several manuscripts have made the analytic approaches
to GWASPA their focus.5,100–104,108 An early method devel-
oped by Wang and colleagues104 uses the gene-set enrich-
ment analysis (GSEA) algorithm to aggregate p values109.
Their approach has beenmotivated by analyses of microar-
ray data where genes in the pathway are ranked by their
strongest empirical p value test statistic. The test statistics
for genes within pathways are aggregated via a Kolmo-
gorov-Smirnov-like running sum. The p value is estimated
by permutations, where the phenotype labels of cases and
controls are permuted a ﬁxed number of times, and the
pathway score is calculated for each permutation. A z score,
which is the difference between the observed value of the
score and the mean of the scores for the permutations
divided by the standard deviation of the scores for the
permutations, provides the overall level of signiﬁcance.
Using this approach, they implicated the involvement of
cell adhesion molecules in autism spectrum disorder (ASD
[MIM 209850]). In a more extensive analysis via the same
approach, the Wnt signaling pathway was studied in type
2 diabetes (NIDDM [MIM 125853]) and did not survive a
p value correction for the testing of multiple pathways.110
More recently, Yu and colleagues103 presented an alter-
native approach to accumulating p values for GWASPA.
They base their analysis on the adaptive rank truncated
product statistic p value, which selects for analysis of the0
k most signiﬁcant genes or the set of genes with a p value
less than a certain threshold. Their analysis optimizes the
selection of truncation points and corrects for multiple
testing by permutation analyses. Through simulation,
they illustrate the important statistical property that the
type 1 error rate is the expected 0.05 under different anal-
yses for two different pathwaymodels, thus indicating that
their permutations successfully correct for the bias intro-
duced by gene and pathway size and SNP density. The
authors also provide a comprehensive analysis of their
method and that of Wang104 and indicate that their
analytic approach is less computationally intensive.
In a very recent example of how GWASPA can be used to
accumulate relatively weak SNP associations, Baranzini
and colleagues111 report the details of a follow-up analysis
of multiple sclerosis. They begin their work with the
premise that many of the SNP associations that have not
been classiﬁed associated under a genome-wide level of
signiﬁcance are in fact true associations with effects that
are too small to detect without their aggregation into path-
ways. Guidance in pathway construction is provided by
known protein interactions and the GO database.112 As
with previous studies, one marker is selected for each
gene in a pathway, and associations occurring in gene
deserts are excluded. In order to identify those pathways
speciﬁc to multiple sclerosis and other autoimmune, neu-
rological, and unrelated diseases, data from the WTCCC
are analyzed in a similar fashion, and their outcomes as
well as pathway randomizations provide the control
results for comparison. More speciﬁcally, the test statistic
accumulates a score by converting the p value for each
gene into a z score that is accumulated over the genes in
the pathway contributing to the score. The expected value
for the sum is derived from a random set of genes from the
genome and their permutations, and the test statistic is
a normal score. The choice of genes to include in the
random set impacts score. A formal discussion of the
features of their statistical approach is not provided, but
a clear description of the method is given. As expected
for preliminary groundbreaking studies, the authors indi-
cate that the interpretation of the implicated pathways
for multiple sclerosis is not straightforward, and their ﬁnd-
ings are somewhat ambiguous.
The statistical methods for GWASPA that have been
described and applied differ mainly in the approach used
to accumulate the associated SNPs. A formal analysis could
clarify whether any of these is expected to be more power-
ful than the others. The methods involve permutation
testing, which can incur a computational burden,
although they address some of the sources of bias. Prob-
lems associated with testing multiple pathways are not
straightforward and remain to be addressed. The most
conservative approach would be a Bonferroni correction,
based on the number of pathways tested, although the
pathways are not necessarily independent. We recom-
mend that each factor in the GWASPA be examined care-
fully before any inferences are drawn, and the mostTheeffective approach to validate the inferences would be
a replication in a comparable independent study sample.
Future Directions
This review focuses on three statistical methods that can be
used to prioritize GWAS results for in-depth follow-up
studies and reveal associations that were not detected
initially. Thus, our ﬁrst suggestion for future studies is to
apply these methods to the available GWAS data following
our recommendations. As the analytic methods evolve and
new approaches are published, the results can be reconsid-
ered and evaluated. Additional suggestions are targeted
toward individuals who are focused on developing statis-
tical methodologies. We enumerate some of the analytic
problems that need solutions below. The WTCCC data
have been used to evaluate some of the methods reviewed
here and may be appropriate for the new ones that are
developed. The available data for these purposes may
increase as studies are published. It is possible that forums
and workshops could be conducted to compare and
improve these methods.
Besides the already discussed challenges of deﬁning
appropriate priors for Bayesian meta-analyses, a number
of challenges exist. As the number of studies increases, so
can heterogeneity and errors. Thus, the development of
better tests of heterogeneity and other post hoc quality-
control measures are needed to improve the reliability of
meta-analysis. Sequence data will increase the number
and nature of the polymorphisms that need to be consid-
ered in a meta-analysis. Thus, we will need methods that
allow incorporation of association results from sequence
data to be combined with SNP chip data in a cumulative
meta-analysis. With a few exceptions,47,48 most meta-
analyses consider the results for each SNP on its own.
Thus, there is a need for highly computationally efﬁcient
methods that can model the effects of multiple SNPs in
a region as well as gene-by-gene interactions.
The challenge for detection of epistasis is better under-
standing of the underlying biological processes rather
than new statistical methods. Elucidation of metabolic
and catabolic processes would help us understand the
effects of the environment. When gene 3 environment
interactions are not adequately taken into account, the
residual trait variation may overwhelm the evidence for
epistasis. In addition, detection of epistatic effects is hand-
icapped by the number of potential tests. Issues regarding
multiple testing can be circumvented by development of
informative priors that capitalize on network relationships
or evidence from realistic animal models.
A number of important analytic issues remain for those
contributing to GWASPA methodology. It is the newest
and least developed approach of the three discussed here.
The most general issue that, if solved, would make
a substantial contribution to these studies would be to
develop a method to examine all possible pathways within
some deﬁned domain so that an unbiased approach could
be taken in identifying the associated pathway (orAmerican Journal of Human Genetics 86, 6–22, January 8, 2010 17
pathways). Such approacheswill be computationally inten-
sive and biologically challenging. The current methods
select the most signiﬁcantly associated SNP from each
gene. But it may be that the pathways with genes having
multiple independent associated SNPs should be weighted
more heavily. GWASPA methods to establish these con-
trasts may be very useful in pathway prioritization. Accu-
mulating the effects of multiple types of mutations in
one analysis can make the statistical power to implicate
pathways substantial, and the emerging methods of
GWASPA should be based on an appeal to this complexity.
Risk alleles for a given disorder may be all common or all
rare, but it is most likely that the alleles will be drawn
from both categories. GWASPA methods should be de-
signed to capture both. Associated alleles in a pathway
may also exhibit epistasis. GWASPA methods should be
developed to include these effects. However, epistasis is
tested by the formal models, and it will not be straightfor-
ward to incorporate this feature. The permutation studies
that are currently being conducted require raw genotype
data, which are not always available. An important meth-
odological improvement would make the p values alone,
and not raw data, the basis of analysis in GWASPA.
In conclusion, although these three statistical approaches
have limitations and analytical challenges, they also
provide a means to prioritize genes for bioinformatics and
laboratory studies focused on identifying causal variants
and their biological roles. In addition, post-GWAS studies
are likely to provide a clearer picture of the true role of
common variants in common complex disorders.Acknowledgments
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